<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096223</url>
  </required_header>
  <id_info>
    <org_study_id>4083-004</org_study_id>
    <nct_id>NCT03096223</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis</brief_title>
  <official_title>A Phase 1, Open-Label, Multiple-Dose Study of KHK4083 in Subjects With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and tolerability of multiple
      intravenous (IV) infusions of KHK4083 in subjects with moderate or severe atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Actual">February 7, 2018</completion_date>
  <primary_completion_date type="Actual">February 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) or drug-related TEAEs and their nature</measure>
    <time_frame>Up to 22 weeks post drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum KHK4083 concentration</measure>
    <time_frame>Up to 22 weeks post drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>Up to 22 weeks post drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (tmax)</measure>
    <time_frame>Up to 22 weeks post drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>Up to 22 weeks post drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-KHK4083 antibody production</measure>
    <time_frame>Up to 22 weeks post drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>KHK4083</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK4083</intervention_name>
    <description>IV administration</description>
    <arm_group_label>KHK4083</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntary written informed consent to participate in the study

          2. Atopic dermatitis diagnosed according to the Definition and Diagnostic Criteria for
             Atopic Dermatitis (Guidelines for Management of Atopic Dermatitis 2016) established by
             the Japanese Dermatological Association

          3. Moderate or severe (≥4.5) symptoms of atopic dermatitis at screening, according to the
             Rajka &amp; Langeland Severity Index

          4. Investigator Global Assessment(IGA) ≥3 (moderate) at screening

        Exclusion Criteria:

          1. Any of the following clinically significant concurrent illnesses:

               -  Type 1 diabetes

               -  Poorly controlled type 2 diabetes (HbA1c &gt;8.5%)

               -  Congestive heart failure (class II to IV of the New York Heart Association
                  classification)

               -  Myocardial infarction within 1 year

               -  Unstable angina pectoris within 1 year

               -  Poorly controlled hypertension (systolic pressure &gt;150 mm Hg or diastolic
                  pressure &gt;90 mm Hg at screening)

               -  Severe chronic lung diseases requiring oxygen therapy

               -  Multiple sclerosis or other demyelinating diseases

               -  Active malignancies, or onset or a history of treatment of malignancies within 5
                  years prior to informed consent (except for resected or surgically cured
                  epithelial carcinoma of the uterine cervix, cutaneous basal cell carcinoma,
                  cutaneous squamous cell carcinoma, or ductal carcinoma)

          2. Current or past history of clinically significant cardiovascular, liver, renal,
             respiratory, hematologic, central nervous system, psychiatric, or autoimmune
             diseases/disorders other than those in 1)

          3. Alcohol dependence, or drug dependence or a positive result for any of the drug abuse
             test items

          4. Past or current history of drug allergy

          5. Any clinically significant infection requiring hospitalization or IV administration of
             antibiotics within 8 weeks prior to pre-enrollment

          6. Any planned surgical treatment during the study

          7. Any skin disease that may affect the clinical symptom assessment

          8. Pregnant or lactating women, or women willing to have a child during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Closed information</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <last_update_submitted>March 25, 2018</last_update_submitted>
  <last_update_submitted_qc>March 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

